Jansen Metaphyseal Chondrodysplasia
What is Jansen Metaphyseal Chondrodysplasia?
Jansen metaphyseal chondrodysplasia is an extremely rare genetic disorder that affects bone growth and calcium balance in the body. It occurs when specific changes, called mutations, happen in the gene that controls how bones respond to parathyroid hormone. This hormone normally helps regulate calcium levels and bone development.
People with this condition have short stature, unusual bone shapes at the growth plates, and elevated calcium levels in their blood. The growth plates are areas near the ends of bones where new bone forms during childhood. When these areas develop abnormally, bones grow shorter and wider than typical.
The condition is so rare that fewer than 30 cases have been documented worldwide. It follows a pattern called autosomal dominant inheritance, meaning only one changed gene copy can cause the disorder. Most cases occur as new mutations with no family history.
Symptoms
- Severe short stature noticeable from infancy
- Bowed legs or knock knees
- Wide and prominent joints, especially at the knees and wrists
- Unusual facial features including a prominent forehead and wide-set eyes
- Muscle weakness and joint stiffness
- Kidney stones due to high calcium levels
- Bone pain or tenderness
- Delayed motor milestones like walking
- High-pitched voice or breathing difficulties
- Dental problems including delayed tooth eruption
Some infants may show symptoms immediately after birth, while others develop signs during early childhood. The severity of symptoms varies between individuals, though growth problems are always present.
Concerned about Jansen Metaphyseal Chondrodysplasia? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
Jansen metaphyseal chondrodysplasia is caused by mutations in the PTH1R gene, which provides instructions for making the parathyroid hormone receptor. This receptor sits on bone and kidney cells and responds to parathyroid hormone signals. When mutations occur, the receptor becomes constantly active even without hormone present. This constant activation tricks the body into behaving as if parathyroid hormone levels are extremely high.
The condition is not caused by lifestyle factors or environmental exposures. Most cases result from new genetic changes that occur spontaneously. There are no known risk factors that increase the chance of developing this mutation. Parents typically have normal genes and do not pass down the condition. However, a person with Jansen metaphyseal chondrodysplasia has a 50 percent chance of passing it to each child.
How it's diagnosed
Diagnosis begins with physical examination noting short stature, skeletal abnormalities, and distinctive facial features. X-rays reveal characteristic changes at the growth plates of long bones, which appear widened and irregular. Blood tests show elevated calcium levels despite low or inappropriately normal parathyroid hormone. This pattern is distinctive because typical hyperparathyroidism shows both high calcium and high PTH.
Genetic testing confirms the diagnosis by identifying PTH1R gene mutations. Testing PTH levels through services like Rite Aid can help identify the unusual hormone pattern that suggests this condition. Your results are processed at Quest Diagnostics locations nationwide. Early blood work helps distinguish Jansen metaphyseal chondrodysplasia from other causes of high calcium and short stature.
Treatment options
- Medications called bisphosphonates to help control calcium levels and protect bones
- Calcium-restricted diet to prevent kidney stones and excessive blood calcium
- Increased fluid intake to reduce kidney stone risk
- Physical therapy to improve joint mobility and muscle strength
- Orthopedic interventions for severe bone deformities
- Growth hormone therapy in some cases, though effectiveness varies
- Regular monitoring of kidney function and calcium levels
- Dental care to address tooth development problems
- Pain management strategies for bone and joint discomfort
- Genetic counseling for families planning future pregnancies
Need testing for Jansen Metaphyseal Chondrodysplasia? Add it to your panel.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
Jansen metaphyseal chondrodysplasia is distinguished by its combination of short stature and elevated blood calcium levels. Most other forms of dwarfism do not affect calcium balance. The characteristic widening of growth plates visible on X-rays also sets this condition apart from other skeletal dysplasias.
The overactive receptor sends constant signals that mimic excessive parathyroid hormone, raising blood calcium levels. The parathyroid glands detect this high calcium and respond by making less hormone through a feedback mechanism. This creates the unusual pattern of high calcium but low or normal PTH that helps doctors identify the condition.
Blood tests reveal important clues but cannot diagnose the condition alone. Testing shows elevated calcium with inappropriately low parathyroid hormone, a distinctive pattern that suggests the diagnosis. Genetic testing is needed to confirm the condition by identifying the specific gene mutation causing symptoms.
Jansen metaphyseal chondrodysplasia follows autosomal dominant inheritance, meaning one mutated gene copy causes the disorder. Most cases occur as new spontaneous mutations with no family history. An affected person has a 50 percent chance of passing the condition to each child.
Elevated calcium can lead to kidney stones, which form when excess calcium crystallizes in the urinary system. High calcium may also cause muscle weakness, fatigue, and digestive problems. Long-term elevation can affect kidney function and may contribute to bone problems beyond those caused by the skeletal dysplasia itself.
People with Jansen metaphyseal chondrodysplasia typically have significant short stature that persists into adulthood. Final adult height is usually well below average, often in the range of 3 to 4 feet tall. Growth hormone therapy has been tried in some cases but shows limited effectiveness for this specific condition.
Monitoring frequency depends on age, symptom severity, and treatment response. Children typically need testing every 3 to 6 months during growth periods. Adults may require less frequent monitoring once calcium levels stabilize with treatment. Your doctor will create a personalized testing schedule based on your individual needs.
Reducing calcium intake helps prevent kidney stones and may slightly lower blood calcium levels. Limiting dairy products, calcium-fortified foods, and calcium supplements is often recommended. However, diet alone cannot fully control the condition because the problem stems from overactive receptors, not excessive calcium consumption.
Because Jansen metaphyseal chondrodysplasia is extremely rare, dedicated support groups may be limited. Many families connect through broader skeletal dysplasia organizations or rare disease networks. Online communities and genetic counseling services can help families connect with others facing similar challenges and share information about managing the condition.
Life expectancy is typically normal with proper medical management. Most people adapt well to their short stature and can lead independent lives. Regular monitoring and treatment help prevent complications from high calcium levels. Early intervention with physical therapy and orthopedic care improves mobility and quality of life.